Nabriva Therapeutics PLC – (NASDAQ:NBRV) was down 7.4% on Thursday . The stock traded as low as $2.65 and last traded at $2.75. Approximately 1,705,742 shares traded hands during mid-day trading, an increase of 84% from the average daily volume of 927,394 shares. The stock had previously closed at $2.97.

Several equities research analysts have recently weighed in on NBRV shares. Zacks Investment Research raised Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Wednesday, January 2nd. BidaskClub raised Nabriva Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, March 14th. Northland Securities reissued a “buy” rating and issued a $12.50 price objective on shares of Nabriva Therapeutics in a research report on Tuesday, March 12th. Gabelli cut Nabriva Therapeutics from a “buy” rating to a “sell” rating and set a $2.56 price objective for the company. in a research report on Wednesday, March 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Nabriva Therapeutics in a research report on Monday, January 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $9.37.

The company has a debt-to-equity ratio of 0.35, a current ratio of 6.11 and a quick ratio of 6.11. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -1.69 and a beta of 2.31.

Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.61 million. Nabriva Therapeutics had a negative return on equity of 101.03% and a negative net margin of 1,188.69%. On average, equities analysts anticipate that Nabriva Therapeutics PLC – will post -1.19 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in Nabriva Therapeutics during the fourth quarter worth $29,000. HRT Financial LLC bought a new position in Nabriva Therapeutics during the fourth quarter worth about $31,000. Two Sigma Advisers LP bought a new position in Nabriva Therapeutics during the fourth quarter worth about $37,000. Paloma Partners Management Co bought a new position in Nabriva Therapeutics during the fourth quarter worth about $54,000. Finally, Wedbush Securities Inc. boosted its holdings in Nabriva Therapeutics by 12.5% during the fourth quarter. Wedbush Securities Inc. now owns 103,550 shares of the biotechnology company’s stock worth $151,000 after buying an additional 11,500 shares during the last quarter. Hedge funds and other institutional investors own 4.62% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/nabriva-therapeutics-nbrv-shares-down-7-4/2955945.html.

Nabriva Therapeutics Company Profile (NASDAQ:NBRV)

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Read More: What does the Dow Jones Industrial Average (DJIA) measure?

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.